Johnson & Johnson said its lung cancer regimen – Rybrevant plus Lazcluze – keeps people alive for at least a year longer than AstraZeneca’s Tagrisso.
More Stories
Delta links its loyalty program to Uber, ending partnership with Lyft
Starting this spring, Delta SkyMiles members will be able to earn loyalty points for Uber rides.
Honda reveals two new ‘0 Series’ EVs to be produced in Ohio
The vehicles are the Honda 0 Saloon, which is an updated version of a concept car revealed last year at...
Frontier plans new flights from JFK to big American Airlines hubs Miami, Los Angeles and Dallas
Frontier said fares would start as low as $19 for JFK-Miami service.
BMW plans to install new ‘panoramic’ display in all vehicles
The new "BMW iDrive" system, including windshield-length display, and "BMW Operating System X" was revealed Tuesday during the CES tech...
Puma challenges Tiger Woods’ Sun Day Red logo
The German sneaker and apparel company says the Sun Day Red logo is too similar to the logo that Puma...
Panera Brands CEO steps down, CFO to fill in as interim chief
The restaurant company, which also includes Einstein Bros. and Caribou Coffee, has been attempting to go public over the last...